-

09:01:12 AM

JNCE Stock News

JNCE - Jounce Therapeutics Inc

03/27/23 9:00 AM

Nasdaq : JNCE

acquisition

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

Jounce Therapeutics, Inc. (NASDAQ: JNCE)

RHEA-AI

neutral

03/16/23 4:30 PM

Nasdaq : JNCE

clinical trial

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian

RHEA-AI

neutral

03/14/23 9:00 PM

Nasdaq : JNCE

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

The Board of Directors (the “Board”) of Jounce

RHEA-AI

neutral

02/23/23 2:30 AM

Nasdaq : JNCE

Redx and Jounce Announce Recommended Business Combination

Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery

RHEA-AI

very positive

02/22/23 5:00 PM

Nasdaq : JNCE

Jounce Therapeutics Announces Restructuring

Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent.

RHEA-AI

neutral

12/27/22 4:30 PM

Nasdaq : GILD, JNCE

acquisition

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811, enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020. “We are pleased to announce the signing of this transaction with Gilead, who have a strong...

RHEA-AI

positive

12/27/22 4:30 PM

Nasdaq : JNCE

acquisition

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq:

RHEA-AI

positive

12/08/22 7:50 AM

Nasdaq : JNCE

clinical trial

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of prior treatment including a PD-1 inhibitor showed a durable partial response with

RHEA-AI

positive

11/10/22 7:00 AM

Nasdaq : JNCE

earnings

Jounce Therapeutics Reports Third Quarter 2022 Financial Results

- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with

RHEA-AI

positive

11/02/22 8:00 AM

Nasdaq : JNCE

Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

JNCE Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitejouncetx.com
CeoRichard Murray
Security nameJounce Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees137
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address780 Memorial Dr
StateMassachusetts
CityCambridge
Zip02139-4613
CountryUS
Phone18572593840

About Jounce Therapeutics Inc

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.